MVMelissa Ana Liriano Vyfhuis

Melissa Ana Liriano Vyfhuis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Melissa Ana Liriano Vyfhuis has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Centering Black Voices: Factors Influencing a Cancer Patient’s Decision to Join a Clinical Trial

    by Charlyn Gomez, Caitlin Eggleston, Matthew Ferris, Jason Molitoris, Zaker Rana, Sarah McAvoy, Elizabeth Nichols, William Regine, Wendla Citron, Søren M. Bentzen, et al.

  • Open Access

    Food Insecurity and Overall Survival in Locally Advanced Breast Cancer Patients Receiving Comprehensive Nodal Irradiation: The Food Insecurity–Obesity Paradox

    by Austin D. Thompson, Lei Hugh Dominic Escobal, Matthew Mathai, Gurbani Singh, Sravya Koduri, Matthew J. Ferris, Sally Cheston, Akshar Patel, Sarah McAvoy, Elizabeth Nichols, et al.

  • Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology

    by Sophia C. Kamran, Monica Borges, Jeff Michalski, W. Robert Lee, Howard M. Sandler, Juanita Crook, Alan Pollack, Mark D. Hurwitz, Richard K. Valicenti, Deborah Watkins Bruner, et al.

    PURPOSE: Precision medicine has revolutionized oncology; however, tumor biomarkers are not reflective of the heterogeneous cancer population. We evaluated NRG Oncology prostate cancer (PCa) clinical trials for demographic differences among patients with optional biospecimen collection (BC) consent and biospecimen submission (BSub). METHODS: Data from 19 NRG PCa clinical trials closed before 2015 were analyzed. Patients who consented to BC and completed BSub were evaluated by race, ethnicity, median income, area deprivation index (ADI; categorized as highest v lowest three quartiles), age at enrollment, site, and year of enrollment. T/chi-square tests were used for continuous/categorical variables, respectively, followed by logistic regression. RESULTS: Of the 15,648 randomized patients eligible for BC, 11,796 (75%) had specimens submitted. In all, 4,598 (82.2%) of 5,597 eligible patients consented for optional BC in nine clinical trials with a separate BC consent process (consent rates by race/ethnicity: 74.1% Black, 72.8% Hispanic/Latino, 83.8% White). A smaller proportion of Black and Hispanic/Latino patients consented to optional BC compared with those who did not (12.1% v 19.5% Black, P < .0001; 3.5% v 5.8% Hispanic, P = .0006). In univariable logistic regression models, high ADI (more socioeconomic disadvantage) was associated with a decreased likelihood for optional BC consent (odds ratio [OR], 0.67 [95% CI, 0.55 to 0.82]; P = .02), but not a decreased likelihood for BSub (OR, 0.74 [95% CI, 0.53 to 1.04]; P = .08). Multivariable models demonstrated that Black/Hispanic/Latino patients were less likely to consent to optional BC, and Black patients were less likely to have BSub ( P < .05 for all). CONCLUSION: White/non-Hispanic patients and those with less socioeconomic disadvantage were more likely to consent to optional BC, whereas Black patients were less likely to have BSub. Targeted solutions are needed to improve biorepository representation so that precision medicine approaches better reflect the cancer population.

  • Impact of a Precision Medicine Navigator on Genomic Test Utilization in Black Patients With Prostate Cancer

    by Alexander J. Allen, Bansi Savla, Claudia Datnow-Martinez, William Mendes, Sophia C. Kamran, Stefan Ambs, Zachery Keepers, Caitlin Eggleston, Kaysee Baker, Jason K. Molitoris, et al.

    PURPOSE: As oncologic precision medicine develops, there is concern that tumor genomic profiling among Black patients and other underrepresented demographics will lag and amplify health disparities. We evaluate whether a precision medicine navigator (PMN), a clinical navigator specialized in obtaining tumor genomic testing for patients, is associated with increased genomic testing rates and whether this is the case among Black patients and other disadvantaged groups. METHODS: We retrospectively reviewed prostate cancer consults within one health care system from November 2, 2021, to January 2, 2023. We compared the proportion of patients who received genomic testing in the 7 months before the PMN start (pre-PMN) to the 7 months afterward (post-PMN). Binary logistic regression was used to calculate the odds of receiving testing. RESULTS: The sample included 693 patients, 311 pre-PMN and 382 post-PMN. Racial distribution and clinical stage were well-balanced between the pre- and post-PMN groups. From pre- to post-PMN, the proportion of patients receiving testing increased from 18% to 70% ( P = .0002). Significant increases in testing post-PMN occurred among Black patients, lower median income patients, patients with Medicare/Medicaid, and community hospital patients. However, utilization post-PMN was significantly higher in non-Black compared with Black patients, 75.4% and 58.5%, respectively ( P = .0006). CONCLUSION: For patients with prostate cancer, the presence of a PMN is associated with increased rates of genomic testing overall, including among Black patients and other groups that experience health inequities. Utilization post-PMN was significantly lower in Black patients compared with non-Black patients. More research is needed into why Black patients show lower rates of genomic testing.

  • Open Access

    Forward momentum: progressive change through diversity equity and inclusion initiatives in academic health care

    by Chaitanya Kalavagunta, Bansi Savla, Jessica White, Dominic Bulkley, Anna Dunlap, Renee Kwok, Kennecia Shaw, Michael MacFarlane, Sara Dudley, David Alicia, et al.

    Background: This study evaluates the impact of a 2-year Diversity, Equity, and Inclusion (DEI) intervention program within a radiation oncology department. We analyzed employee perceptions of inclusivity, bias, training, and career development, recognizing the challenges of assessing DEI initiatives in an evolving sociopolitical context. Methods: A voluntary survey was distributed in 2021 and 2023. The survey assessed 4 DEI domains: Inclusivity, Department Bias, Training/Education, and Career Development. Responses were analyzed using nonparametric tests. DEI initiatives included implicit bias training, allyship training, book clubs, anonymous feedback platforms, and a DEI website. Results: Survey completion rates were 40% (2021) and 50% (2023). Significant improvements were observed in Inclusivity (3.72 vs 3.91, P = .042), Training/Education (3.57 vs 4.14, P < .001), and Career Development (3.39 vs 3.60, P = .019). Department Bias showed no significant change (P = .130). Anti-DEI sentiment increased in 2023, highlighting challenges in fostering inclusivity. Subgroup analyses revealed improvements for Black employees but persistent disparities for women. Conclusions: This exploratory study suggests that targeted DEI initiatives can improve employee perceptions of workplace culture in academic health-care settings. Notably, the program improved perceptions of inclusivity, training opportunities, and career development. However, persistent gender inequities in training and career development highlight the need for monitoring and focused efforts. These findings can inform future DEI strategies and underscore the importance of continued vigilance in promoting an inclusive work environment. Future research should explore the program’s downstream effects on patient care, clinical trial enrollment, and residency enrollment.


  • Open Access

    Cancer outcomes and cardiopulmonary toxicities for Black patients with breast cancer treated with proton therapy

    by Gurbani Singh, Sravya Koduri, Manaahil Rao, Meira Kidorf, Sarah Ruff, Akshar Patel, Søren M Bentzen, Elizabeth Nichols, Sarah McAvoy, Melissa A L Vyfhuis

    Background: Black women have a 40% higher breast cancer mortality rate than White women and are at a higher risk of acquiring cardiovascular disease. Proton therapy can be used to mitigate cardiac radiation exposure; however, proton therapy remains a scarce resource in the United States. We report on the cardiovascular profiles of patients undergoing proton therapy to determine the potential benefit of the therapy for Black women compared with patients of other races. Methods: We retrospectively analyzed 599 patients with breast cancer who received proton therapy from June 2016 to December 2021 at the Maryland Proton Treatment Center. A variety of sociodemographic, disease, and treatment variables were analyzed using descriptive statistics. Results: With a median follow-up of 26 months (range = 0.47-90 months), Black patients made up 31.6% of the population and presented with higher rates of hypertension (P < .001), cardiopulmonary conditions (P < .001), and a higher median body mass index (P = .015) compared with the other cohort, a trend that persisted at the time of post–proton therapy follow-up. Black women had higher rates of triple-negative disease (P < .001), with subsequent greater receipt of neoadjuvant chemotherapy (P = .039). Pulmonary events were 2.6 times more likely to occur in Black patients than in the non-Black cohort after proton therapy (odds ratio = 2.60, 95% CI = 1.39 to 4.88; P = .003). Conclusions: Black women presenting for proton therapy had higher baseline risks of cardiovascular co-morbidities combined with more aggressive breast cancer biology and a subsequent 2.6-fold increased risk of pulmonary events after proton therapy. Our findings support the use of advanced radiation techniques as a means of sparing important organs at risk, especially in historically marginalized populations.


  • Open Access

    Identifying Nutritional Inequities of Patients with Cancer Residing in Food Deserts

    by Lara LePore, Dahlia Kronfli, Kaysee Baker, Caitlin Eggleston, Kaitlin Schotz, Amber S. Kleckner, Søren M. Bentzen, Pranshu Mohindra, Melissa A.L. Vyfhuis


  • Dietary Counseling Interventions During Radiation Therapy: A Systematic Review of Feasibility, Safety, and Efficacy

    by Alexie Oppermann, Shalet James, Mackenzie M. Minotti, Kaitlin M. Schotz, Martha E. Francis, Ian R. Kleckner, Melissa A. L. Vyfhuis, Matthew J. Ferris, Brenton J. Baguley, Amber S. Kleckner

    Radiotherapy is a common cancer treatment, and concurrent nutritional interventions can maintain nutritional status and improve clinical and supportive care outcomes. However, optimal nutritional interventions during radiotherapy are not firmly established. Herein, we assessed the feasibility, safety, and efficacy of dietary counseling interventions without oral nutrition supplements on health outcomes in adults receiving radiotherapy for cancer in a systematic review. Prospective clinical trials that implemented nutritional counseling interventions during radiotherapy were identified from four databases from inception through December 2023. Feasibility, safety, and efficacy were extracted from 32 articles that described 23 randomized and 4 non-randomized clinical trials. The interventions included individualized nutritional counseling (n = 14 articles), nutritional counseling plus exercise (n = 4), and nutritional counseling focused on increasing or reducing intake of specific nutrients (n = 9). Trials targeted head and neck (n = 12), pelvic cancers (n = 14), and/or breast (n = 5) cancers. Control groups had variable designs and included general nutrition education and intervention as needed. Studies recruited 120 ± 104 participants (range 26-468). Interventions tended to be feasible regarding retention and attendance at sessions, though feasibility metrics varied among different interventions. Most interventions were safe with no studies reporting adverse events attributable to dietary intervention. Individualized dietary counseling interventions tended to lead to between-group differences favoring the intervention group in regard to improved nutritional status, maintenance or attenuation of loss of body mass, improved quality of life, and reduced radiation-induced toxicities. Diets that encouraged/discouraged specific nutrients tended to recruit patients receiving radiation to the pelvic area and resulted in positive or neutral effects on gastrointestinal symptoms. In conclusion, nutritional interventions appear to be feasible, safe, and effective during radiotherapy for various symptom outcomes.


  • Psychosocial Factors That Influence a Woman's Decision to Enroll in a Clinical Trial: Implications on How to Improve Clinical Trial Enrollment Among Black Women

    by Uma Markan, Kaysee Baker, Caitlin Eggleston, Sally B. Cheston, Pranshu Mohindra, Elizabeth Nichols, Sarah McAvoy, Søren M. Bentzen, Melissa A.L. Vyfhuis